Current Alzheimer ResearchCurrent Alzheimer ResearchCurrent Alzheimer Research1567-20501875-582864374210.2174/0115672050315334240508162754MedicineResearch ArticleEffects of Cycloastragenol on Alzheimer's Disease in Rats by Reducing Oxidative Stress, Inflammation, and ApoptosisAlharbiKadiinfo@benthamscience.netAlshehriShahadinfo@benthamscience.netAlmarwaniWasayfinfo@benthamscience.netAljohaniKhuludinfo@benthamscience.netAlbalawiAjwaninfo@benthamscience.netAlatawiAreejinfo@benthamscience.netAl-AtwiShekhainfo@benthamscience.netAlhwytyLamainfo@benthamscience.netHassanHananinfo@benthamscience.netAl-GayyarMohammedinfo@benthamscience.netPharmD Program, Faculty of Pharmacy, University of TabukDepartment of Pharmacology and Biochemistry, Faculty of Pharmacy, Delta University for Science and TechnologyDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University0102202421214115407012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1567-2050/article/view/643742

Background:As individuals age, they may develop Alzheimer's disease (AD), which is characterized by difficulties in speech, memory loss, and other issues related to neural function. Cycloastragenol is an active ingredient of Astragalus trojanus and has been used to treat inflammation, aging, heart disease, and cancer.

Objectives:This study aimed to explore the potential therapeutic benefits of cycloastragenol in rats with experimentally induced AD. Moreover, the underlying molecular mechanisms were also evaluated by measuring Nrf2 and HO-1, which are involved in oxidative stress, NFκB and TNF-α, which are involved in inflammation, and BCL2, BAX, and caspase-3, which are involved in apoptosis.

Methods:Sprague-Dawley rats were given 70 mg/kg of aluminum chloride intraperitoneally daily for six weeks to induce AD. Following AD induction, the rats were given 25 mg/kg of cycloastragenol daily by oral gavage for three weeks. Hippocampal sections were stained with hematoxylin/ eosin and with anti-caspase-3 antibodies. The Nrf2, HO-1, NFκB, TNF-α, BCL2, BAX, and caspase-3 gene expressions and protein levels in the samples were analyzed.

Results:Cycloastragenol significantly improved rats' behavioral test performance. It also strengthened the organization of the hippocampus. Cycloastragenol significantly improved behavioral performance and improved hippocampal structure in rats. It caused a marked decrease in the expression of NFκB, TNF-α, BAX, and caspase-3, which was associated with an increase in the expression of BCL2, Nrf2, and HO-1.

Conclusion:Cycloastragenol improved the structure of the hippocampus in rats with AD. It enhanced the outcomes of behavioral tests, decreased the concentration of AChE in the brain, and exerted antioxidant and anti-inflammatory effects. Antiapoptotic effects were also noted, leading to significant improvements in cognitive function, memory, and behavior in treated rats.

Acetylcholinesterase (AchE)Alzheimer&amprsquos disease (AD)B-cell lymphoma 2 (BCL2)Bcl-2-associated x protein (BAX)Caspase-3heme oxygenase-1 (HO-1)Nuclear factor erythroid 2-related factor 2 (Nrf2)Nuclear factor κB (NFκB)Tumor necrosis factor-α (TNF-α).Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s Disease: Causes and treatment. Molecules 2020; 25(24): 5789. doi: 10.3390/molecules25245789 PMID: 33302541Zhang Y, Kiryu H. Identification of oxidative stress-related genes differentially expressed in Alzheimer’s disease and construction of a hub gene-based diagnostic model. Sci Rep 2023; 13(1): 6817. doi: 10.1038/s41598-023-34021-1 PMID: 37100862Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 2021; 8(3): 1-9. doi: 10.14283/jpad.2021.15 PMID: 34101789Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the Cholinergic System. Curr Neuropharmacol 2016; 14(1): 101-15. doi: 10.2174/1570159X13666150716165726 PMID: 26813123Wang R, Reddy PH. Role of glutamate and NMDA receptors in alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1041-8. doi: 10.3233/JAD-160763 PMID: 27662322Bagalagel A, Diri R, Noor A, et al. The therapeutic effects of cycloastragenol in ulcerative colitis by modulating SphK/ MIP-1α/miR-143 signalling. Basic Clin Pharmacol Toxicol 2022; 131(5): 406-19. doi: 10.1111/bcpt.13788 PMID: 36029292Yu Y, Zhou L, Yang Y, Liu Y. Cycloastragenol: An exciting novel candidate for age-associated diseases (Review). Exp Ther Med 2018; 16(3): 2175-82. doi: 10.3892/etm.2018.6501 PMID: 30186456Güven L, Erturk A, Miloğlu FD, Alwasel S, Gulcin İ. Screening of antiglaucoma, antidiabetic, anti-alzheimer, and antioxidant activities of Astragalus alopecurus pall—analysis of phenolics profiles by LC-MS/MS. Pharmaceuticals (Basel) 2023; 16(5): 659. doi: 10.3390/ph16050659 PMID: 37242442Dong Q, Li Z, Zhang Q, Hu Y, Liang H, Xiong L. Astragalus mongholicus Bunge (Fabaceae): Bioactive compounds and potential therapeutic mechanisms against Alzheimer’s disease. Front Pharmacol 2022; 13: 924429. doi: 10.3389/fphar.2022.924429 PMID: 35837291Bahaeddin Z, Yans A, Khodagholi F, Sahranavard S. Dietary supplementation with Allium hirtifolium and/or Astragalus hamosus improved memory and reduced neuro-inflammation in the rat model of Alzheimer’s disease. Appl Physiol Nutr Metab 2018; 43(6): 558-64. doi: 10.1139/apnm-2017-0585 PMID: 29262273Wankhede NL, Kale MB, Upaganlawar AB, et al. Involvement of molecular chaperone in protein-misfolding brain diseases. Biomed Pharmacother 2022; 147: 112647. doi: 10.1016/j.biopha.2022.112647 PMID: 35149361Ajmal MR. Protein misfolding and aggregation in proteinopathies: Causes, mechanism and cellular response. Diseases 2023; 11(1): 30. doi: 10.3390/diseases11010030 PMID: 36810544Samman WA, Selim SM, El Fayoumi HM, El-Sayed NM, Mehanna ET, Hazem RM. Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced alzheimer’s disease via modulation of AMPK/mTOR, oxidative stress and glucose metabolism. Pharmaceuticals (Basel) 2023; 16(5): 753. doi: 10.3390/ph16050753 PMID: 37242536Abd El-Aziz NMA, Shehata MG, Alsulami T, et al. Characterization of orange peel extract and its potential protective effect against aluminum chloride-induced alzheimer’s disease. Pharmaceuticals (Basel) 2022; 16(1): 12. doi: 10.3390/ph16010012 PMID: 36678510Bayomi HS, Elsherbiny NM, El-Gayar AM, Al-Gayyar MMH. Evaluation of renal protective effects of inhibiting TGF-β type I receptor in a cisplatin-induced nephrotoxicity model. Eur Cytokine Netw 2013; 24(4): 139-47. doi: 10.1684/ecn.2014.0344 PMID: 24590376Alshehri A, Albuhayri A, Alanazi M, et al. Effects of Echinacoside on Ehrlich Carcinoma in rats by targeting proliferation, hypoxia and inflammation. Cureus 2023; 15(10): e46800. doi: 10.7759/cureus.46800 PMID: 37822691Alfair BM, Jabarti AA, Albalawi SS, Khodir AE, Al-Gayyar MM. Arctiin inhibits inflammation, fibrosis, and tumor cell migration in rats with ehrlich solid carcinoma. Cureus 2023; 15(9): e44987. doi: 10.7759/cureus.44987 PMID: 37701157Albalawi AZ, Alatawi AS, Al-Atwi SM. Echinacoside ameliorates hepatic fibrosis and tumor invasion in rats with thioacetamide-induced hepatocellular carcinoma. Biomol Biomed 2024; 2024: 10367. doi: 10.17305/bb.2024.10367Al-Gayyar MMH, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biol Chem 2016; 397(3): 257-67. doi: 10.1515/hsz-2015-0265 PMID: 26733159Alatawi YF, Alhablani MA, Al-Rashidi FA, et al. Garcinol-attenuated Gastric Ulcer (GU) experimentally induced in rats via affecting inflammation, cell proliferation, and DNA polymerization. Cureus 2023; 15(8): e43317. doi: 10.7759/cureus.43317 PMID: 37577271Alghamdi MA, Khalifah TA, Alhawati HS, et al. Antitumor activity of ferulic acid against ehrlich solid carcinoma in rats via affecting hypoxia, oxidative stress and cell proliferation. Cureus 2023; 15(7): e41985. doi: 10.7759/cureus.41985 PMID: 37465088Alshehri SA, Almarwani WA, Albalawi AZ, et al. Role of arctiin in fibrosis and apoptosis in experimentally induced hepatocellular carcinoma in rats. Cureus 2024; 16(1): e51997. doi: 10.7759/cureus.51997 PMID: 38205087Kandimalla R, Vallamkondu J, Corgiat EB, Gill KD. Understanding aspects of aluminum exposure in Alzheimer’s Disease Development. Brain Pathol 2016; 26(2): 139-54. doi: 10.1111/bpa.12333 PMID: 26494454Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and alzheimer’s disease. J Alzheimers Dis 2017; 57(4): 1105-21. doi: 10.3233/JAD-161088 PMID: 28059794He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci 2020; 21(13): 4777. doi: 10.3390/ijms21134777 PMID: 32640524Duvigneau JC, Esterbauer H, Kozlov AV. Role of heme oxygenase as a modulator of heme-mediated pathways. Antioxidants 2019; 8(10): 475. doi: 10.3390/antiox8100475 PMID: 31614577De Plano LM, Calabrese G, Rizzo MG, Oddo S, Caccamo A. The role of the transcription factor Nrf2 in alzheimer’s disease: Therapeutic opportunities. Biomolecules 2023; 13(3): 549. doi: 10.3390/biom13030549 PMID: 36979483Liu R, Yang J, Li Y, Xie J, Wang J. Heme oxygenase-1: The roles of both good and evil in neurodegenerative diseases. J Neurochem 2023; 167(3): 347-61. doi: 10.1111/jnc.15969 PMID: 37746863Chen T, Li Z, Li S, et al. Cycloastragenol suppresses M1 and promotes M2 polarization in LPS-stimulated BV-2 cells and ischemic stroke mice. Int Immunopharmacol 2022; 113(Pt A): 109290. doi: 10.1016/j.intimp.2022.109290 PMID: 36252498Wang G, Ma C, Chen K, et al. Cycloastragenol attenuates osteoclastogenesis and bone loss by targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, calcium, and NFATc1 pathways. Front Pharmacol 2022; 12: 810322. doi: 10.3389/fphar.2021.810322 PMID: 35126144Judd JM, Jasbi P, Winslow W, et al. Inflammation and the pathological progression of Alzheimer’s disease are associated with low circulating choline levels. Acta Neuropathol 2023; 146(4): 565-83. doi: 10.1007/s00401-023-02616-7 PMID: 37548694Sivamaruthi BS, Raghani N, Chorawala M, et al. NF-κB pathway and its inhibitors: A promising frontier in the management of alzheimer’s disease. Biomedicines 2023; 11(9): 2587. doi: 10.3390/biomedicines11092587 PMID: 37761028Jin J, Guang M, Li S, et al. Immune-related signature of periodontitis and Alzheimer’s disease linkage. Front Genet 2023; 14: 1230245. doi: 10.3389/fgene.2023.1230245 PMID: 37849501Li M, Li S, Dou B, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin 2020; 41(8): 1025-32. doi: 10.1038/s41401-020-0386-6 PMID: 32203080Ren Y, Li H, Yao J, et al. Application quantitative proteomics approach to identify differentially expressed proteins associated with cardiac protection mediated by cycloastragenol in acute myocardial infarction rats. J Proteomics 2020; 222: 103691. doi: 10.1016/j.jprot.2020.103691 PMID: 32068187Haiyan H, Yiyu W, Yihui Z, et al. Effect of Qingxinkaiqiao compound on cortical mRNA expression of the apoptosis-related genes Bcl-2, BAX, caspase-3, and Aβ in an Alzheimer’s disease rat model. J Tradit Chin Med 2016; 36(5): 654-62. doi: 10.1016/S0254-6272(16)30086-3 PMID: 29933535Su JH, Satou T, Anderson AJ, Cotman CW. Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimerʼs disease. Neuroreport 1996; 7(2): 437-40. doi: 10.1097/00001756-199601310-00015 PMID: 8730800Callens M, Kraskovskaya N, Derevtsova K, et al. The role of Bcl-2 proteins in modulating neuronal Ca2+ signaling in health and in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res 2021; 1868(6): 118997. doi: 10.1016/j.bbamcr.2021.118997 PMID: 33711363Berridge MJ. Vitamin D, reactive oxygen species and calcium signalling in ageing and disease. Philos Trans R Soc Lond B Biol Sci 2016; 371(1700): 20150434. doi: 10.1098/rstb.2015.0434 PMID: 27377727Ureshino RP, Bertoncini CR, Fernandes MJS, et al. Alterations in calcium signaling and a decrease in Bcl-2 expression: Possible correlation with apoptosis in aged striatum. J Neurosci Res 2010; 88(2): 438-47. doi: 10.1002/jnr.22214 PMID: 19774672Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 2008; 28(12): 3051-9. doi: 10.1523/JNEUROSCI.5620-07.2008 PMID: 18354008Khezri MR, Ghasemnejad-Berenji M, Moloodsouri D. The PI3K/AKT signaling pathway and caspase-3 in alzheimer’s disease: Which one is the beginner? J Alzheimers Dis 2023; 92(2): 391-3. doi: 10.3233/JAD-221157 PMID: 36776071Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S. Neuronal cell death mechanisms in Alzheimer’s disease: An insight. Front Mol Neurosci 2022; 15: 937133. doi: 10.3389/fnmol.2022.937133 PMID: 36090249Hong H, Xiao J, Guo Q, et al. Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells against high glucose-induced senescence and apoptosis. Exp Ther Med 2021; 22(5): 1326. doi: 10.3892/etm.2021.10761 PMID: 34630680Szabo NJ. Dietary safety of cycloastragenol from Astragalus spp.: Subchronic toxicity and genotoxicity studies. Food Chem Toxicol 2014; 64: 322-34. doi: 10.1016/j.fct.2013.11.041 PMID: 24316212